Wells Fargo & Company Aquestive Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 32,336 shares of AQST stock, worth $136,781. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,336
Previous 24,065
34.37%
Holding current value
$136,781
Previous $102,000
17.65%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AQST
# of Institutions
98Shares Held
42.7MCall Options Held
271KPut Options Held
212K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$41.5 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$23.5 Million1.58% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$23.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.23MShares$17.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.85MShares$12.1 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $226M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...